Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Chief Development Officer | December 18, 2020 | December 22, 2020 |
| Atrium Therapeutics, Inc.RNA · Entity 6185 | Chief Medical Officer | September 18, 2026 | September 22, 2026 |
| VivoSim Labs, INC.ONVO · Entity 8386 | Chief Medical Officer | August 16, 2019 | August 19, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcturus Therapeutics Holdings Inc.
Report date December 18, 2020 · Filed December 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.29 · Expires 2030-12-18 | Direct | 50,000 |
Reported balance
After 2020-12-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-18 · Grant · Acquired 50,000 · Balance 50,000 F1: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.
Atrium Therapeutics, Inc.
Report date September 18, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,638 |
Reported balance
After 2026-09-18 transaction · row 1
1 source rowRow 1 · 2026-09-18 · Tax withholding · Disposed 21,459 · Balance 51,638 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
VivoSim Labs, INC.
Report date August 16, 2019 · Filed August 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 138,484 |
Reported balance
After 2019-08-16 transaction · row 1
1 source rowRow 1 · 2019-08-16 · Sale · Disposed 22,230 · Balance 138,484 F1: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $0.2859 to $0.2921. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $0.2859 to $0.2921. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avidity Biosciences, Inc.
Report date February 27, 2026 · Filed February 27, 2026
Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Disposition to issuer · Disposed 115,857 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.96 · Expires 2032-02-13 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-27 · Disposition to issuer · Disposed 73,342 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.47 · Expires 2033-01-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Disposition to issuer · Disposed 74,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.57 · Expires 2033-09-10 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-27 · Disposition to issuer · Disposed 49,333 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.16 · Expires 2034-01-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-27 · Disposition to issuer · Disposed 68,458 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.42 · Expires 2035-01-05 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-27 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 22, 2026 20:23 UTC | Atrium Therapeutics, Inc. RNA · Entity 6185 | Tax withholdingCommon Stock | 21,459 | $8.95 | $192,058.05 |
DisclosureSEC source: 0001193125-26-397967 · ownership.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,638 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 17:54 UTC | Atrium Therapeutics, Inc. RNA · Entity 6185 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $14.30 | $0.00 |
DisclosureSEC source: 0001193125-26-170963 · ownership.xml · derivative · entry 2 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-04-20 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 17:54 UTC | Atrium Therapeutics, Inc. RNA · Entity 6185 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-170963 · ownership.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,097 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:20 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $31.42 | Not disclosed |
DisclosureSEC source: 0001193125-26-082277 · ownership.xml · derivative · entry 6 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2035-01-05 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:20 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 68,458 | Not disclosed Strike: $10.16 | Not disclosed |
DisclosureSEC source: 0001193125-26-082277 · ownership.xml · derivative · entry 5 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 68,458 shares Expires 2034-01-19 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:20 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 49,333 | Not disclosed Strike: $6.57 | Not disclosed |
DisclosureSEC source: 0001193125-26-082277 · ownership.xml · derivative · entry 4 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,333 shares Expires 2033-09-10 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:20 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 74,000 | Not disclosed Strike: $22.47 | Not disclosed |
DisclosureSEC source: 0001193125-26-082277 · ownership.xml · derivative · entry 3 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,000 shares Expires 2033-01-19 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:20 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 73,342 | Not disclosed Strike: $15.96 | Not disclosed |
DisclosureSEC source: 0001193125-26-082277 · ownership.xml · derivative · entry 2 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,342 shares Expires 2032-02-13 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:20 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerCommon Stock | 115,857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-082277 · ownership.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. F1 · price: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 22:34 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 2,878 | $72.45 | $208,511.10 |
DisclosureSEC source: 0001599901-26-000026 · wk-form4_1769207644.xml · nonDerivative · entry 2 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,599 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2026 and the sale of the resulting shares of common stock on January 21, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 22:34 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 2,017 | $72.45 | $146,131.65 |
DisclosureSEC source: 0001599901-26-000026 · wk-form4_1769207644.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,477 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2026 and the sale of the resulting shares of common stock on January 21, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:12 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 2,373 | $72.23 | $171,401.79 |
DisclosureSEC source: 0001599901-26-000009 · wk-form4_1767996760.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,494 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 6, 2026 and the sale of the resulting shares of common stock on January 7, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 20:56 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,209 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0001599901-25-000200 · wk-form4_1761339397.xml · derivative · entry 3 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,458 Underlying: Common Stock · 2,209 shares Expires 2034-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F3 · derivative.exercise_date: This option was granted on January 20, 2024 and vests in equal installments of 2,208 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 20:56 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 2,209 | $47.54 | $105,014.53 |
DisclosureSEC source: 0001599901-25-000200 · wk-form4_1761339397.xml · nonDerivative · entry 2 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,867 F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.83 to $49.30. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 20:56 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 2,209 | $10.16 | $22,443.44 |
DisclosureSEC source: 0001599901-25-000200 · wk-form4_1761339397.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| September 22, 2025 Filed Sep 23, 2025 20:57 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,208 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0001599901-25-000190 · wk-form4_1758661054.xml · derivative · entry 3 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,667 Underlying: Common Stock · 2,208 shares Expires 2034-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · derivative.exercise_date: This option was granted on January 20, 2024 and vests in equal installments of 2,208 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028. Read SEC document |
| September 22, 2025 Filed Sep 23, 2025 20:57 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 2,208 | $40.58 | $89,600.64 |
DisclosureSEC source: 0001599901-25-000190 · wk-form4_1758661054.xml · nonDerivative · entry 2 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,867 F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| September 22, 2025 Filed Sep 23, 2025 20:57 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 2,208 | $10.16 | $22,433.28 |
DisclosureSEC source: 0001599901-25-000190 · wk-form4_1758661054.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:02 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,542 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0001599901-25-000186 · wk-form4_1758139329.xml · derivative · entry 3 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,333 Underlying: Common Stock · 1,542 shares Expires 2033-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of September 11, 2023 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the option shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:02 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 1,542 | $45.41 | $70,022.22 |
DisclosureSEC source: 0001599901-25-000186 · wk-form4_1758139329.xml · nonDerivative · entry 2 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,867 F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:02 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 1,542 | $6.57 | $10,130.94 |
DisclosureSEC source: 0001599901-25-000186 · wk-form4_1758139329.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| August 22, 2025 Filed Aug 22, 2025 21:20 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,208 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0001599901-25-000166 · wk-form4_1755897597.xml · derivative · entry 3 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,875 Underlying: Common Stock · 2,208 shares Expires 2034-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F3 · derivative.exercise_date: This option was granted on January 20, 2024 and vests in equal installments of 2,208 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028. Read SEC document |
| August 22, 2025 Filed Aug 22, 2025 21:20 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 2,208 | $46.40 | $102,461.58 |
DisclosureSEC source: 0001599901-25-000166 · wk-form4_1755897597.xml · nonDerivative · entry 2 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,867 F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.64 to $47.03. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 22, 2025 Filed Aug 22, 2025 21:20 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 2,208 | $10.16 | $22,433.28 |
DisclosureSEC source: 0001599901-25-000166 · wk-form4_1755897597.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 20:07 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,542 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0001599901-25-000159 · wk-form4_1755288434.xml · derivative · entry 3 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,875 Underlying: Common Stock · 1,542 shares Expires 2033-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · derivative.exercise_date: This option was granted on September 11, 2023 and vests in equal installments of 1,542 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on September 11, 2027. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 20:07 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 1,542 | $46.66 | $71,949.72 |
DisclosureSEC source: 0001599901-25-000159 · wk-form4_1755288434.xml · nonDerivative · entry 2 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,867 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 20:07 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 1,542 | $6.57 | $10,130.94 |
DisclosureSEC source: 0001599901-25-000159 · wk-form4_1755288434.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,667 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0001599901-25-000150 · wk-form4_1754689169.xml · derivative · entry 13 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,083 Underlying: Common Stock · 17,667 shares Expires 2034-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F6 · derivative.exercise_date: This option was granted on January 20, 2024 and vests in equal installments of 2,208 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,167 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001599901-25-000150 · wk-form4_1754689169.xml · derivative · entry 12 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 6,167 shares Expires 2033-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F5 · derivative.exercise_date: This option was granted on January 20, 2023 and vests in equal installments of 3,083 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2027. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,334 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0001599901-25-000150 · wk-form4_1754689169.xml · derivative · entry 11 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,417 Underlying: Common Stock · 12,334 shares Expires 2033-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F4 · derivative.exercise_date: This option was granted on September 11, 2023 and vests in equal installments of 1,542 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on September 11, 2027. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,283 | $0.00 Strike: $15.96 | $0.00 |
DisclosureSEC source: 0001599901-25-000150 · wk-form4_1754689169.xml · derivative · entry 10 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,342 Underlying: Common Stock · 11,283 shares Expires 2032-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F3 · derivative.exercise_date: This option was granted on February 14, 2022 and vests in equal installments of 5,652 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on February 14, 2026. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 33,983 | $42.74 | $1,452,341.67 |
DisclosureSEC source: 0001599901-25-000150 · wk-form4_1754689169.xml · nonDerivative · entry 9 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,867 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.15 to $46.44. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 17,667 | $42.74 | $755,039.88 |
DisclosureSEC source: 0001599901-25-000150 · wk-form4_1754689169.xml · nonDerivative · entry 8 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,850 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.15 to $46.44. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 17,667 | $10.16 | $179,496.72 |
DisclosureSEC source: 0001599901-25-000150 · wk-form4_1754689169.xml · nonDerivative · entry 7 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 6,167 | $42.74 | $263,560.93 |
DisclosureSEC source: 0001599901-25-000150 · wk-form4_1754689169.xml · nonDerivative · entry 6 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,850 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.15 to $46.44. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 6,167 | $22.47 | $138,572.49 |
DisclosureSEC source: 0001599901-25-000150 · wk-form4_1754689169.xml · nonDerivative · entry 5 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 12,334 | $42.74 | $527,121.86 |
DisclosureSEC source: 0001599901-25-000150 · wk-form4_1754689169.xml · nonDerivative · entry 4 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,850 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.15 to $46.44. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 12,334 | $6.57 | $81,034.38 |
DisclosureSEC source: 0001599901-25-000150 · wk-form4_1754689169.xml · nonDerivative · entry 3 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 11,283 | $42.74 | $482,204.96 |
DisclosureSEC source: 0001599901-25-000150 · wk-form4_1754689169.xml · nonDerivative · entry 2 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,850 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.15 to $46.44. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:39 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 11,283 | $15.96 | $180,076.68 |
DisclosureSEC source: 0001599901-25-000150 · wk-form4_1754689169.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 22:44 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 9,578 | $31.06 | $297,490.76 |
DisclosureSEC source: 0001599901-25-000075 · wk-form4_1742597049.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,850 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of 25,000 time-based restricted stock units (RSUs) that vested on March 19, 2025. Those RSUs were initially granted as performance-based restricted stock units (PSUs), and converted to time-based RSUs as a result of a performance objective achieved by the Issuer on September 19, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.05 to $31.06. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 24, 2025 01:06 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 2,032 | $28.59 | $58,096.10 |
DisclosureSEC source: 0001599901-25-000031 · wk-form4_1737680795.xml · nonDerivative · entry 2 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,428 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2025 and the sale of the resulting shares of common stock on January 21, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F3 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.59 to $28.69. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 24, 2025 01:06 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 1,915 | $28.60 | $54,760.38 |
DisclosureSEC source: 0001599901-25-000031 · wk-form4_1737680795.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,460 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2025 and the sale of the resulting shares of common stock on January 21, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.59 to $29.47. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 01:22 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $31.42 | $0.00 |
DisclosureSEC source: 0001599901-25-000019 · wk-form4_1736385741.xml · derivative · entry 2 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-01-05 F2 · derivative.exercise_date: This option vests in 48 equal installments on each monthly anniversary of the grant date, until it is fully vested on January 6, 2029. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 01:22 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-25-000019 · wk-form4_1736385741.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,375 F1 · shares: Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 6, 2025, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 19:39 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $99.29 | $0.00 |
DisclosureSEC source: 0001193805-20-001607 · e620161_4-hughes.xml · derivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-12-18 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 20:04 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $14.12 | $0.00 |
DisclosureSEC source: 0000899243-20-005386 · doc4.xml · derivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-02-18 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 22:22 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | SaleCommon Stock | 22,230 | $0.29 | $6,431.14 |
DisclosureSEC source: 0001209191-19-046693 · doc4.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,484 F1 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $0.2859 to $0.2921. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 23:04 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 974,694 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-18-046894 · doc4.xml · derivative · entry 2 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,694 Underlying: Common Stock · 974,694 shares Expires 2028-08-14 F2 · derivative.exercise_date: 25% of the option shares vest and become exercisable on August 15, 2019 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 23:04 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantCommon Stock | 160,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-046894 · doc4.xml · nonDerivative · entry 1 Hughes Steven George · CIK 0001747528 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,714 F1 · shares: The shares represent a grant of Restricted Stock Units ("RSUs"). The RSUs represent a right to receive shares of the Issuer's common stock, at no additional conversion or exercise price. 25% of the RSUs vest and settle on August 15, 2019 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.